SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer headquartered in Sydney, Australia, on October 9, 2013. The filing serves to report a specific corporate governance event rather than providing periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement and contains no quantitative financial data.
Material Changes
The material change disclosed in this filing is a change in a director's interest, as detailed in the attached Exhibit 99.1 (Appendix 3Y - Change of Director's Interest Notice). No other operational or financial changes are described in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the director's interest change.
Key Facts for Investor Verification
- Verify the specific details of the director's interest change referenced in Exhibit 99.1.
- Confirm the identity of the director whose interest has changed.
- Note that this filing does not contain financial performance data for the period.